Clearance of chronic HCV infection during acute delta hepatitis

K Deterding1, S V Pothakamuri, V Schlaphoff

  • 1Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany.

Infection
|December 18, 2007
PubMed

Insights

Hepatitis C (HCV) was cleared during acute hepatitis B/D superinfection. This recovery was linked to a robust T cell response against hepatitis D virus (HDV), suggesting bystander mechanisms for HCV clearance and potential immunotherapy strategies.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • The clinical course of chronic hepatitis C (HCV) during acute hepatitis D virus (HDV) and hepatitis B virus (HBV) superinfection remains unclear.
  • Understanding immune responses during viral superinfections is crucial for developing effective treatments.

Observation:

  • A patient with chronic hepatitis C experienced spontaneous clearance of HCV.
  • This clearance occurred during an acute, self-limited superinfection with both hepatitis B and D viruses.
  • The recovery from HCV correlated with a strong, multispecific T cell response targeting HDV.

Findings:

  • Hepatitis D virus (HDV)-specific memory CD4+ and CD8+ T cell responses were prominent following superinfection.
  • Hepatitis C virus (HCV)-specific CD4+ T cell responses were notably weak despite HCV clearance.
  • The data indicate that clearance of chronic HCV can be mediated by bystander immune mechanisms during acute viral superinfections.

Implications:

  • These findings suggest that acute superinfections can trigger immune responses capable of clearing chronic HCV.
  • Bystander immune activation during viral infections may represent a novel therapeutic avenue for treating chronic hepatitis C.
  • Further research into these mechanisms could inform the development of new immunotherapies for HCV.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Drug Elimination: The Concept of Clearance01:06

Drug Elimination: The Concept of Clearance

Drug elimination refers to removing drugs from the body, either through urine by the kidneys or through bile by the liver. Drug clearance is a pharmacokinetic parameter that measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the plasma concentration of the drug.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...